Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Node Positive HER2 Negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02756364
What this trial is testing

Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy

Who this might be right for
Breast Neoplasms
Calithera Biosciences, Inc 141
Testing effectiveness (Phase 2)Study completedNCT00856492
What this trial is testing

S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer

Who this might be right for
Breast Cancer
SWOG Cancer Research Network 215
Early research (Phase 1)Study completedNCT04647487
What this trial is testing

LY3484356 in Women With Breast Cancer Before Having Surgery

Who this might be right for
Breast Cancer
Eli Lilly and Company 87
Not applicableWithdrawnNCT02102438
What this trial is testing

Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast Cancer

Who this might be right for
Breast CancerHER-2 Positive Breast Cancer
Instituto do Cancer do Estado de São Paulo
Large-scale testing (Phase 3)Looking for participantsNCT04263298
What this trial is testing

Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Herui Yao 210
Not applicableStudy completedNCT04524728
What this trial is testing

Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy

Who this might be right for
BreastNeoplasm MalignantFemale
Istituti Clinici Scientifici Maugeri SpA 191
Testing effectiveness (Phase 2)Looking for participantsNCT07396324
What this trial is testing

Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer

Who this might be right for
HR-positive/HER2-negative Breast Cancer
RenJi Hospital 55
Testing effectiveness (Phase 2)Active Not RecruitingNCT05296746
What this trial is testing

Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer

Who this might be right for
Breast Cancer Stage II
SOLTI Breast Cancer Research Group 1,100
Large-scale testing (Phase 3)Ended earlyNCT03439046
What this trial is testing

Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 287
Large-scale testing (Phase 3)Study completedNCT01626222
What this trial is testing

4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 301
Testing effectiveness (Phase 2)Looking for participantsNCT06167694
What this trial is testing

Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer

Who this might be right for
Unresectable or Metastatic Breast Cancer
Shandong Suncadia Medicine Co., Ltd. 146
Testing effectiveness (Phase 2)Looking for participantsNCT06450873
What this trial is testing

Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery

Who this might be right for
Estrogen Receptor-Positive Breast CarcinomaHER2-Negative Breast Carcinoma
Mayo Clinic 40
Early research (Phase 1)Ended earlyNCT03816839
What this trial is testing

Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)

Who this might be right for
Breast Cancer
Sanofi 10
Early research (Phase 1)Looking for participantsNCT05304962
What this trial is testing

FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Regor Pharmaceuticals Inc. 64
Testing effectiveness (Phase 2)Looking for participantsNCT07427394
What this trial is testing

Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
AstraZeneca 24
Testing effectiveness (Phase 2)UnknownNCT04760431
What this trial is testing

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)

Who this might be right for
HER2-positive Breast CancerBrain Metastases
Second Affiliated Hospital, Zhejiang University, School of Medicine 120
Not applicableLooking for participantsNCT06744465
What this trial is testing

NearWave Optical Molecular Monitoring

Who this might be right for
Breast CancerHER2-positive Breast CancerTNBC - Triple-Negative Breast Cancer+2 more
Indiana University 15
Early research (Phase 1)WithdrawnNCT03285607
What this trial is testing

MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer

Who this might be right for
Breast CancerCancer of Breast
Washington University School of Medicine
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07748208
What this trial is testing

A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes

Who this might be right for
Breast CancerDiabetes Type II
Hoffmann-La Roche 40
Testing effectiveness (Phase 2)Looking for participantsNCT06953882
What this trial is testing

Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy

Who this might be right for
HER2 Negative Breast Cancer
Yale University 140
Next Page